Seeking Alpha

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Healio

Measurements for HCV cure could be done earlier among people who inject drugs

People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...
KTVZ

Housing Works to open waiting list for 2026 Housing Choice Voucher Program next week

Housing Works, a housing organization dedicated to fostering stability and affordability in Central Oregon, has announced ...
Nasdaq

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...